Drug Trial Radar · NCT04040322
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Oct 14, 2019
Primary completion
Jun 9, 2021
Study completion Jun 9, 2021
Sponsor
- Lead sponsor
- Civi Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.
Conditions
- Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusionDrug
Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Iloprost Injection, for intravenous useDrug
Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Frequency of Symptomatic RP AttacksTime frame: From baseline (Day 10 to Day 25 of screening period) to the end ofthe efficacy follow-up (Day 8 to Day 21).
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Research, PLLC
Phoenix, Arizona
Mayo Clinic - Scottsdale
Scottsdale, Arizona
University of Arizona - Arthritis Research Center
Tucson, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
University of California, Los Angeles Medical Center
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
University of California San Francisco
San Francisco, California
Georgetown University Medical Center - Department of Rheumatology
Washington D.C., District of Columbia
Northwestern Medical Faculty Foundation
Chicago, Illinois
University Medical Center New Orleans
New Orleans, Louisiana
Johns Hopkins University School of Medicine
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
West Michigan Rheumatology PLLC
Grand Rapids, Michigan
University of Minnesota Maple Grove
Minneapolis, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Robert Wood Johnson Medical School
New Brunswick, New Jersey
Hospital for Special Surgery
New York, New York
Columbia University Medical Center
New York, New York
University of Cincinnati - Scleroderma Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
The University of Toledo Medical Center (UTMC) - Ruppert Health Center
Toledo, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics
Houston, Texas
University of Utah
Salt Lake City, Utah
Virginia Mason Medical Center
Seattle, Washington
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.